Cover Image
市場調查報告書

大日本住友製藥的產品平台分析

Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 321961
出版日期 內容資訊 英文 103 Pages
訂單完成後即時交付
價格
Back to Top
大日本住友製藥的產品平台分析 Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review - 2016
出版日期: 2016年12月30日 內容資訊: 英文 103 Pages
簡介

大日本住友製藥正在開發、製造並商品化中樞神經系統(CNS),心血管系統,糖尿病,癌症,感染疾病等領域的各種醫藥產品。同時也提供動物用醫藥品,食品添加物,診斷用藥,研究用材料等,更在研究本部進行創新的新藥研究。

本報告提供大日本住友製藥 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

大日本住友製藥 基本資料

  • 大日本住友製藥 概要
  • 主要資訊
  • 企業資料

大日本住友製藥 :R&D概要

  • 主要的治療範圍

大日本住友製藥 :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

大日本住友製藥 :開發中產品概況

  • 後期階段產品開發中產品
    • 登記申請前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

大日本住友製藥 :藥物簡介

  • amrubicin hydrochloride
  • blonanserin
  • droxidopa
  • lurasidone hydrochloride
  • ranirestat
  • vatiquinone
  • afacifenacin
  • DSP-6952
  • obeticholic acid
  • zonisamide
  • EPI-589
  • WT-2725
  • WT-4869
  • DSP-0011
  • DSR-6434
  • NEP-28
  • SM-276001
  • SM-295291
  • SM-324405
  • SM-369926
  • Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia
  • Small Molecule to Inhibit Soluble Epoxide Hydrolase for Renal Protection
  • Small Molecules to Activate Translocator Protein for Anxiety
  • Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis
  • Small Molecules to Inhibit Phosphodiesterase 4 for Asthma and Inflammation
  • Small Molecules to Target Ras Signaling Pathway for Cancer
  • Apoptosis Inhibitor Of Macrophages
  • HLS-001
  • Small Molecule to Antagonize GCGR for Type 2 Diabetes
  • Small Molecule to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes
  • Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease
  • Small Molecules to Inhibit CaMKII for Undisclosed Indication
  • Small Molecules to Inhibit mPGES-1 for Inflammation

大日本住友製藥 :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

大日本住友製藥 :最新的開發平台資訊

大日本住友製藥 :中止開發的計劃

大日本住友製藥 :開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • emapunil
    • rafabegron
    • ceftaroline fosamil
    • DSP-0565
    • DSP-3025
    • DSP-7238
    • DSP-9599
    • KGA-3235
    • limaprost
    • rafabegron
    • ranirestat
    • resequinil
    • rimacalib
    • SEP-225425
    • SEP-226332
    • SEP-227162
    • SEP-227900
    • SMP-028
    • SMP-797

大日本住友製藥 :企業理念

大日本住友製藥 :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08194CDB

Summary

Global Markets Direct's, 'Sumitomo Dainippon Pharma Co Ltd - Product Pipeline Review - 2016', provides an overview of the Sumitomo Dainippon Pharma Co Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sumitomo Dainippon Pharma Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Sumitomo Dainippon Pharma Co Ltd
  • The report provides overview of Sumitomo Dainippon Pharma Co Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Sumitomo Dainippon Pharma Co Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Sumitomo Dainippon Pharma Co Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Sumitomo Dainippon Pharma Co Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sumitomo Dainippon Pharma Co Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sumitomo Dainippon Pharma Co Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sumitomo Dainippon Pharma Co Ltd Snapshot
    • Sumitomo Dainippon Pharma Co Ltd Overview
    • Key Facts
  • Sumitomo Dainippon Pharma Co Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline Products Glance
    • Sumitomo Dainippon Pharma Co Ltd - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Sumitomo Dainippon Pharma Co Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities <
      li>Phase I Products/Combination Treatment Modalities
    • Sumitomo Dainippon Pharma Co Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Sumitomo Dainippon Pharma Co Ltd - Drug Profiles
    • amrubicin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • blonanserin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-0011 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-1200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-6952 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-7888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSR-17759 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSR-6434 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSR-71167 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSR-98776 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EPI-589 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HLS-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lurasidone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEP-28 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • obeticholic acid - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-276001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-295291 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SM-369926 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Epilepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Pruritus - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize Muscarinic Acetylcholine Receptor 4 for Schizophrenia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Dipeptidyl Peptidase IV for Type 2 Diabetes - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Soluble Epoxide Hydrolase for Renal Protection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Translocator Protein for Anxiety - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CaMKII for Undisclosed Indication - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit mPGES-1 for Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Phosphodiesterase 4 for Asthma and Inflammation - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target Ras Signaling Pathway for Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SMP-304 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vatiquinone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WT-2725 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • WT-4869 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • zonisamide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline Analysis
    • Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Target
    • Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Route of Administration
    • Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Molecule Type
    • Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Mechanism of Action
  • Sumitomo Dainippon Pharma Co Ltd - Dormant Projects
  • Sumitomo Dainippon Pharma Co Ltd - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ceftaroline fosamil
      • DSP-0565
      • DSP-3025
      • DSP-7238
      • DSP-9599
      • emapunil
      • indiplon
      • KGA-3235
      • limaprost
      • rafabegron
      • ranirestat
      • razupenem
      • resequinil
      • rimacalib
      • SEP-225425
      • SEP-226332
      • SEP-227162
      • SEP-227900
      • SMP-028
      • SMP-797
  • Sumitomo Dainippon Pharma Co Ltd - Company Statement
  • Sumitomo Dainippon Pharma Co Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sumitomo Dainippon Pharma Co Ltd, Key Facts
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Indication, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Stage of Development, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Monotherapy Products in Pipeline, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Partnered Products in Pipeline, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Out-Licensed Products in Pipeline, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pre-Registration, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Phase III, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Phase II, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Phase I, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Preclinical, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Discovery, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Target, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Route of Administration, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Molecule Type, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Mechanism of Action, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Dormant Developmental Projects,2016
  • Sumitomo Dainippon Pharma Co Ltd - Discontinued Pipeline Products, 2016
  • Sumitomo Dainippon Pharma Co Ltd, Other Locations
  • Sumitomo Dainippon Pharma Co Ltd, Subsidiaries

List of Figures

  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Top 10 Indication, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Stage of Development, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Monotherapy Products in Pipeline, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Partnered Products in Pipeline, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Out-Licensed Products in Pipeline, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Top 10 Target, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Route of Administration, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline by Top 10 Molecule Type, 2016
  • Sumitomo Dainippon Pharma Co Ltd - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top